Issue 05

REGULATION AND LEGISLATION


Oregonian Congressman supports measure for the legalisation of psilocybin therapy.


Psychedelic decriminalisation petition awaits Canadian government response.


The Australian TGA is reviewing the prospect of treating PTSD patients with MDMA.


Colorado Health Department plans to review the use of ketamine by first responders.

BUSINESS AND INVESTMENT


Dr. Matthew Johnson joins David Nutt and Ben Sessa at AWAKN Life Sciences.


ATAI launches subsidiary EmpathBio, developing derivatives of MDMA for PTSD.


A new mushroom focussed brand house from the creators of High12.


Newton Energy enters into an amalgamation agreement with Field Trip Psychedelics.


Natural soap company, Dr. Bronner launches campaign for psychedelic-assisted therapy.


MindMed announces world’s first clinical trial combining MDMA with LSD.


Ehave announces psychedelic retreats through its Mycotopia Therapy subsidiary.


Compass Pathways, a UK mental health company plans to file for US IPO on the Nasdaq.

RESEARCH AND SCIENCE


Psychedelic Group, MAPS, raises US$30 million for MDMA study on PTSD.


Growing numbers of young people are microdosing during lockdown.


New research finds that placebo pills have the ability to induce psychedelic-like effects.


Small LSD microdosing clinical trial reports promising effects for pain relief.

THE PSYCHEDELICS AS MEDICINE REPORT

Legal psychedelic therapies can offer cost savings of hundreds of billions of dollars.
Psychedelic-assisted therapies have been experiencing a resurgence in interest across clinical trials, scientific studies and commercial investment. As the industry develops, we examine the potential cost savings of legalising psychedelic-assisted therapies across the EU and US.

The Psychedelics as Medicine Report

Medical psychedelics are experiencing a renaissance, pushing forward the frontiers of healthcare innovation.
PSYCH: The Psychedelics as Medicine Report provides unparalleled insights and intelligence from industry experts and market leaders, helping to guide investors, operators and regulators through this transient phase.

Download your free copy now.

REACH GLOBAL INVESTORS

Exclusive sponsorship opportunities still available

PSYCH: The Psychedelics as Medicine Report Second Edition launches this month, presenting the most comprehensive analysis of the latest global developments, medical advancements as well as our exclusive market insights on this burgeoning industry.

For sponsorship information, get in touch with our global sponsorship manager, Will Sloane.

Will@prohibitionpartners.com